11 active not recruiting, 6 recruiting, 2 terminated, 1 completed. 12 Phase 1, 11 Phase 2, 3 Phase 3.
Follow Locally Advanced Urothelial Carcinoma: new trials by email Literature Review of Locally Advanced Urothelial Carcinoma trials Research Report on Locally Advanced Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma EB-DT-NK-UC101, Cyclophosphamide, Fludarabine - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-03-25 |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer Biospecimen Collection, Carboplatin, Cisplatin - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 320 | 2025-12-02 | 2026-10-05 |
| Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma Radical cystectomy - Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma | Phase 2 | Recruiting | Yale University | 32 | 2025-11-26 | 2026-10-07 |
| A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab - Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 38 | 2024-07-17 | 2026-02-18 |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program Home Health Encounter, Nivolumab, Patient Monitoring - Advanced Esophageal Squamous Cell Carcinoma, Advanced Renal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 50 | 2024-04-30 | 2026-10-02 |
| Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma Enfortumab vedotin, Pembrolizumab - Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 60 | 2023-06-14 | 2026-03-19 |
| Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations TYRA-300 - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Tyra Biosciences, Inc | 310 | 2022-11-22 | 2026-01-12 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy Pembrolizumab, Nivolumab, Atezolizumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 3 | 2022-05-27 | 2026-03-20 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma Belinostat, Durvalumab - Infiltrating Urothelial Carcinoma, Sarcomatoid Variant, Locally Advanced Urothelial Carcinoma | Phase 1 | Completed | University of Utah | 7 | 2022-01-14 | 2026-10-14 |
| Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib Balversa - Bladder Cancer, Urothelial Carcinoma | Terminated | xCures | 2 | 2021-11-21 | 2022-12-22 | |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer Cabozantinib S-malate, Enfortumab Vedotin, Quality-of-Life Assessment - Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma | Phase 1 | Recruiting | Emory University | 32 | 2021-07-23 | 2026-04-29 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma Pembrolizumab, Selinexor - Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1 / Phase 2 | Terminated | Mamta Parikh | 4 | 2021-04-08 | 2026-01-29 |
| Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors Pembrolizumab, Sonidegib - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8 | Phase 1 | Active not recruiting | Mayo Clinic | 36 | 2020-02-13 | 2026-03-18 |
| Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 30 | 2019-11-18 | 2026-07-31 |
| Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer Biospecimen Collection, Clinical Observation, Computed Tomography - Localized Renal Pelvis and Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 739 | 2017-11-03 | 2026-10-26 |
Showing 20 of 21. Sign in to see all of them.
Carcinoma, Transitional Cell (19) · Urinary Bladder Neoplasms (8) · Ureteral Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Melanoma (3) · Neoplasm Metastasis (3) · Squamous Cell Carcinoma of Head and Neck (3) · Urethral Neoplasms (3) · Carcinoma, Hepatocellular (2) · Carcinoma, Renal Cell (2) · Lung Neoplasms (2) · Carcinoma, Lobular (1) · Carcinoma, Merkel Cell (1) · Carcinosarcoma (1) · Colorectal Neoplasms (1)
Neoplasms (20) · Carcinoma (19) · Neoplasms by Histologic Type (19) · Neoplasms, Glandular and Epithelial (19) · Neoplasms by Site (12) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Male Urogenital Diseases (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Urologic Diseases (11) · Urologic Neoplasms (10) · Urinary Bladder Diseases (8) · Ureteral Diseases (4) · Bronchial Neoplasms (3)
pembrolizumab (11) · Specimen Handling (5) · enfortumab vedotin (5) · Magnetic Resonance Spectroscopy (4) · Nivolumab (4) · Cyclophosphamide (2) · Immunoglobulin G (2) · avelumab (2) · durvalumab (2) · erdafitinib (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · ALT-803 (1) · Biopsy (1) · Carboplatin (1) · Cisplatin (1)
National Cancer Institute (NCI) (5) · Mayo Clinic (3) · Emory University (2) · Alliance for Clinical Trials in Oncology (1) · Beijing Biotech (1) · Fox Chase Cancer Center (1) · ImmunityBio, Inc. (1) · M.D. Anderson Cancer Center (1) · Mamta Parikh (1) · Merck Sharp & Dohme LLC (1) · Tyra Biosciences, Inc (1) · University of Utah (1) · Yale University (1) · xCures (1)
United States (20) · Canada (3) · France (2) · Spain (2) · Australia (1) · China (1) · Guam (1) · Israel (1) · Italy (1) · Netherlands (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Andrea B Apolo (1) · Daniel J. George, MD (1) · David I Quinn (1) · Doug Warner (1) · Fed Ghali, MD (1) · Jacqueline Brown, MD (1) · Maha H Hussain (1) · Mamta Parikh (1) · Mehmet A Bilen, MD (1) · Mojun Zhu, M.D. (1) · Monika Joshi (1) · Pooja Ghatalia, MD (1) · Rohit Jain (1) · Roxana S. Dronca, M.D. (1)
P30CA138292 (2), U10CA180821 (2), 2023 (1), N01CM00038 (1), N01CM00071 (1), N01CM62201 (1), N01CM62209 (1), P30CA033572 (1), P30CA060553 (1), P30CA093373 (1), U01CA062505 (1), U10CA180820 (1), UM1CA186644 (1), UM1CA186705 (1), UM1CA186717 (1)